Synlogic (SYBX) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYBX shares.
View SYBX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12-month price objectives for Synlogic's stock. Their SYBX share price forecasts range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 1,796.2% from the stock's current price.
View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts.

Synlogic's stock was trading at $0.76 at the beginning of 2023. Since then, SYBX stock has decreased by 56.1% and is now trading at $0.3340.
View the best growth stocks for 2023 here.

Synlogic saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 192,400 shares, a decrease of 25.7% from the August 15th total of 259,100 shares. Based on an average trading volume of 188,100 shares, the short-interest ratio is presently 1.0 days. Approximately 0.4% of the shares of the stock are sold short.
View Synlogic's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SYBX earnings forecast.

Synlogic, Inc. (NASDAQ:SYBX) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company earned $0.04 million during the quarter, compared to the consensus estimate of $0.18 million. Synlogic had a negative trailing twelve-month return on equity of 85.18% and a negative net margin of 6,573.82%.

Synlogic shares reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.44%), Harbor Capital Advisors Inc. (0.43%), Renaissance Technologies LLC (0.31%) and PVG Asset Management Corp (0.10%). Insiders that own company stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen.
View institutional ownership trends.

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $0.33.

Synlogic (NASDAQ:SYBX) has a market capitalization of $22.91 million and generates $1.18 million in revenue each year. The biotechnology company earns $-66,150,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for the company is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.